Ingredients

A good CDMO is a true partner with advice on getting the most from your molecule.

CPhI Worldwide will return on October 9-11, 2018, at the IFEMA, Feria de Madrid, Spain.

Interest in cannabinoid drug development is growing. The potential market – and the opportunity to treat unmet patient needs – is enormous.

Enzyme engineering has opened up new possibilities in biocatalysis, but computational techniques and smart libraries also make wildtypes feasible. The choice is yours.

Why we shouldn’t forget gelatin’s longstanding reputation as a reliable and trusted excipient.

Here, James speaks with Christophe Le Ret from Umicore.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

The Medicine Maker's James Strachan speaks with Paul Evans from Johnson Matthey.

The Medicine Maker's William Aryitey speaks with Dago Caceres from Dow Pharmaceuticals.